This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Post
Newsramp
newsramp.com
did:plc:xlsujlrwr5xpfxgaf4pixhri
Regentis Biomaterials $RGNT reports a 400% production yield increase for GelrinC following European regulatory approval of its new manufacturing process. Its U.S. Phase III SAGE trial is now 50%+ enrolled, targeting 470,000 annual knee cartilage repair cases. #Orthopedics #Biotech
2026-08-14T20:01:16.863Z